A Study to Evaluate the Efficacy of MuGard for the Amelioration of Oral Mucositis in Head and Neck Cancer Patients

Inclusion Criteria:

Subjects will be included in the study if they:

1. Are willing and able to understand and sign an informed consent form (ICF) for the
study approved by the Investigator's local or a central Institutional Review Board
(IRB) or Independent Ethics Committee (IEC)

2. Are males or females aged 18 years or older

3. Have recently-diagnosed, pathologically-confirmed cancer of the head and neck (e.g.,
oral cavity, oropharynx, hypopharynx, larynx; nasopharynx, lips, sinuses, salivary
glands, or unknown primary)that will be treated with CRT (with or without induction
therapy prior to CRT)

4. Have a plan to receive a continuous course of conventional external beam irradiation
delivered as single daily fractions of 2.0 Gy to 2.2 Gy with a cumulative radiation
dose between 50 Gy and 72 Gy with concomitant chemotherapy. Planned radiation
treatment fields must include at least two oral sites (buccal mucosa, floor of mouth,
tongue, soft palate) with each site receiving at least 50 Gy

5. Have Karnofsky performance score (KPS) >= 80% or Eastern Cooperative Oncology Group
(ECOG) score of <= 1 (See Appendix B and C for KPS and ECOG scores respectively)

6. Have the ability to comply with the MuGard product insert

Exclusion Criteria:

Subjects will be excluded from participation in the study if they:

1. Have major surgical procedure or significant traumatic injury within 2 weeks prior to
the initiation of RT or anticipation of need for major surgical procedure during the
course of the study

2. Have active infectious disease excluding oral candidiasis

3. Have presence of oral mucositis

4. Have chronic immunosuppression

5. Have use of any investigational agent within 30 days of randomization

6. Are female subjects who are pregnant or breastfeeding

7. Have known allergies or intolerance to MuGard Mucoadhesive Oral Wound Rinse, its
ingredients, or the ingredients used in the sham control. The ingredients which
appear in either formulation are as follows: benzalkonium chloride, benzyl alcohol,
carbopol 971P, citric acid, glycerin, polysorbate 60, phosphoric acid, purified
Water, sodium bicarbonate, sodium chloride, sodium saccharin

8. Have inability to give informed consent or comply with study requirements

9. Are unwilling to or unable to complete the subject diary

10. Have any other condition or prior therapy that in the opinion of the Investigator
would make the subject unsuitable for the study or unable to comply with follow-up
visits